Endo International plc, et al.

Track this case

Case overview

Case Number:

7:22-bk-22549

Court:

New York Southern

Nature of Suit:

Firms

Companies

Government Agencies

Sectors & Industries:

  1. September 14, 2022

    US Trustee Says Endo Can't Justify $71M In Bonus Pay

    The U.S. Trustee's Office is asking a New York bankruptcy judge to reject Endo Pharmaceuticals' request to make bonus payments to its employees, saying the opioid maker has failed to justify the more than $71 million in payments.

  2. September 12, 2022

    Endo Seeks Injunction To Pause Government Opioid Suits

    Endo Pharmaceuticals is asking a New York bankruptcy judge to pause thousands of state and local government suits against the company over its opioid sales, saying it needs breathing room to finish its Chapter 11 reorganization.

  3. August 22, 2022

    Endo Unit Seeks To Stop Termination Of Drug License Deal

    An Endo International affiliate Monday asked a New York bankruptcy judge to prevent another pharmaceutical company from canceling pre-Chapter 11 asset purchase and drug licensing deals, denying that it breached the contracts.

  4. August 18, 2022

    Endo Noteholders Say Alternative Ch. 11 Plan Needed

    Creditors of Endo International told a New York bankruptcy judge Thursday that they will seek to file an alternative to Endo's proposed Chapter 11 sale, as the drugmaker made its first court appearance in its bankruptcy case.

  5. August 17, 2022

    Ch. 11 Cheat Sheet: Endo International PLC

    Besieged by opioid crisis lawsuits, drugmaker Endo International has filed for Chapter 11 protection in a New York bankruptcy court, saying a deal will cut $6 billion in debt and earmark $550 million for claims it contributed to an epidemic of narcotic abuse.

  6. August 17, 2022

    Endo Hits Ch. 11 Amid Opioid Suit Crush

    Besieged by opioid crisis lawsuits, drugmaker Endo International has filed for Chapter 11 protection in a New York bankruptcy court, saying a deal will cut $6 billion in debt and earmark $550 million for claims it contributed to an epidemic of narcotic abuse.